Modalis Therapeutics

Modalis Therapeutics Corporation is a biotechnology company focused on developing precision genetic medicines for orphan genetic diseases through its proprietary epigenetic gene modulation platform. The company was founded in January 2016 as EdiGene Corporation by Haru Morita and Osamu Nureki, and it changed its name to Modalis Therapeutics in August 2019. It is headquartered in Tokyo, Japan, with research and development facilities in Waltham, Massachusetts, USA. Modalis Therapeutics went public on the Tokyo Stock Exchange Mothers market in August 2020.

The company's core technology is CRISPR-GNDM® (Guide Nucleotide-Directed Modulation), an advanced epigenome editing technology that enables the locus-specific modulation of gene expression or histone modification without requiring double-stranded DNA cleavage. This "cut-free CRISPR" technology combines a dCas9 enzyme (which lacks cleavage activity) with an epigenome modulator and a guide RNA to precisely target and regulate the expression of specific genes. The system is designed to be delivered to target cells using adeno-associated virus (AAV) vectors, offering the potential for long-lasting therapeutic effects from a single dose.

Modalis Therapeutics operates on a hybrid business model that includes both in-house and collaborative development pipelines. In its in-house model, the company develops its own therapeutic candidates before potentially licensing them to partners for later-stage development and commercialization. In the collaborative model, Modalis partners with other companies to develop therapies for targets selected by the partner. This dual approach allows the company to generate revenue through upfront payments, development milestones, and royalties on future sales, mitigating the high costs and long timelines of pharmaceutical development.

The company's development pipeline is focused on rare genetic diseases with high unmet medical needs, particularly muscular disorders, diseases of the central nervous system, and cardiovascular disease. Key programs include MDL-101 for Congenital Muscular Dystrophy type 1A (LAMA2-CMD), which has received Orphan Drug Designation from the U.S. FDA, and MDL-103 for Facioscapulohumeral Muscular Dystrophy (FSHD). As a pre-commercial, R&D-driven biotech, the company has not yet generated operating revenue and focuses on reinvesting capital into advancing its therapeutic pipeline.

Keywords: Epigenetic editing, CRISPR-GNDM, gene modulation, orphan diseases, rare genetic disorders, gene therapy, AAV vector, LAMA2-CMD, muscular dystrophy, precision medicine, nucleic acid therapeutics, genome engineering, drug development, biotechnology, preclinical, Tokyo Stock Exchange, CRISPR therapeutics, DUX4, FSHD, central nervous system diseases.